GENinCode (LON:GENI) Stock Price Down 20% – Should You Sell?

GENinCode Plc (LON:GENI) shares fell 20% on Tuesday. The company traded as low as GBX 0.64 and last traded at GBX 0.70. Approximately 22,954,143 shares changed hands during mid-day trading, an increase of 346% from the average daily volume of 5,146,545 shares. The stock had previously closed at GBX 0.88.

GENinCode Stock Down 20.0%

The company has a quick ratio of 15.88, a current ratio of 0.93 and a debt-to-equity ratio of 117.74. The firm has a market capitalization of £5.27 million, a PE ratio of -0.34 and a beta of 0.59. The business’s 50-day moving average price is GBX 0.88 and its 200-day moving average price is GBX 0.99.

GENinCode (LON:GENI) last announced its quarterly earnings data on Tuesday, September 29th. The company reported GBX (0.38) EPS for the quarter. GENinCode had a negative net margin of 185.47% and a negative return on equity of 409.40%. As a group, equities research analysts predict that GENinCode Plc will post -7.1299999 EPS for the current fiscal year.

GENinCode Company Profile

GENinCode Plc is a UK based company specialising in genetic risk assessment of cardiovascular disease. Cardiovascular disease is the leading cause of death and disability worldwide.

GENinCode operates business units in the UK, in the United States through GENinCode U.S. Inc and in Europe through GENinCode S.L.U.

GENinCode predictive technology provides patients and physicians with globally leading preventative care and treatment strategies. GENinCode CE marked invitro-diagnostic molecular tests combine clinical algorithms and bioinformatics to provide advanced patient risk assessment to predict disease onset.